The Hemostatic and Thrombotic Complications of Liver Disease

Overview

Journal Eur J Haematol

Specialty Hematology

Date 2021 Jul 14

PMID 34258797

Citations 7

Authors

Hannah Stowe McMurry

Janice Jou

Joseph Shatzel

Affiliations

Soon will be listed here.

Abstract

Hepatic cirrhosis leads to numerous hematologic derangements resulting in a complex and tenuously rebalanced hemostatic milieu. The utility of common hematologic tests including the INR and aPTT in assessing hemostatic and thrombotic risk in patients with cirrhosis is limited, and consensus on transfusion thresholds and proper management of thrombotic complications continues to evolve. This review summarizes the pathophysiology of key derangements of hemostasis including those of platelets, von Willebrand factor, pro- and anticoagulation factors, and fibrin. Additionally, the pathogenesis, consequences, optimal management, and prevention of major thrombotic and bleeding complications in cirrhosis arte discussed.

Citing Articles

Development and validation of an integrated model for the diagnosis of liver cirrhosis with portal vein thrombosis combined with endoscopic characters and blood biochemistry data: a retrospective propensity score matching (PSM) cohort study.

Yang J, Zhang X, Chen J, Hou X, Shi M, Yin L Ann Med. 2025; 57(1):2457521.

PMID: 39881530 PMC: 11784028. DOI: 10.1080/07853890.2025.2457521.

Phytonadione Utilization and the Risk of Bleeding in Chronic Liver Disease.

He J, Cox T, Gilbert B Hosp Pharm. 2024; 59(6):660-665.

PMID: 39465095 PMC: 11500214. DOI: 10.1177/00185787241269114.

Hematological abnormalities in liver cirrhosis.

Fierro-Angulo O, Gonzalez-Regueiro J, Pereira-Garcia A, Ruiz-Margain A, Solis-Huerta F, Macias-Rodriguez R World J Hepatol. 2024; 16(9):1229-1244.

PMID: 39351511 PMC: 11438588. DOI: 10.4254/wjh.v16.i9.1229.

Enhanced venous thrombosis and hypercoagulability in murine and human metabolic dysfunction-associated steatohepatitis.

Pandey N, Anand S, Kaur H, Richard K, Chandaluri L, Butler M J Thromb Haemost. 2024; 22(12):3572-3580.

PMID: 39306095 PMC: 11608147. DOI: 10.1016/j.jtha.2024.08.023.

Coagulation Dysfunctions in Non-Alcoholic Fatty Liver Disease-Oxidative Stress and Inflammation Relevance.

Robea M, Balmus I, Girleanu I, Huiban L, Muzica C, Ciobica A Medicina (Kaunas). 2023; 59(9).

PMID: 37763733 PMC: 10535217. DOI: 10.3390/medicina59091614.

References

Amitrano L, Guardascione M, Brancaccio V, Margaglione M, Manguso F, Iannaccone L . Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol. 2004; 40(5):736-41. DOI: 10.1016/j.jhep.2004.01.001. View

Lisman T, Leebeek F, de Groot P . Haemostatic abnormalities in patients with liver disease. J Hepatol. 2002; 37(2):280-7. DOI: 10.1016/s0168-8278(02)00199-x. View

Villanueva C, Colomo A, Bosch A, Concepcion M, Hernandez-Gea V, Aracil C . Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013; 368(1):11-21. DOI: 10.1056/NEJMoa1211801. View

Dalmau A, Sabate A, Acosta F, Garcia-Huete L, Koo M, Sansano T . Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation. Anesth Analg. 2000; 91(1):29-34. DOI: 10.1097/00000539-200007000-00006. View

Lisman T, Porte R . Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood. 2010; 116(6):878-85. DOI: 10.1182/blood-2010-02-261891. View

Escolar G, Cases A, Vinas M, Pino M, Calls J, Cirera I . Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100 ): influence of hematocrit elevation. Haematologica. 1999; 84(7):614-9. View

Northup P, Friedman L, Kamath P . AGA Clinical Practice Update on Surgical Risk Assessment and Perioperative Management in Cirrhosis: Expert Review. Clin Gastroenterol Hepatol. 2018; 17(4):595-606. DOI: 10.1016/j.cgh.2018.09.043. View

Lisman T, Bongers T, Adelmeijer J, Janssen H, de Maat M, de Groot P . Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology. 2006; 44(1):53-61. DOI: 10.1002/hep.21231. View

Vinholt P, Hvas A, Nielsen C, Soderstrom A, Sprogoe U, Fialla A . Reduced platelet activation and platelet aggregation in patients with alcoholic liver cirrhosis. Platelets. 2017; 29(5):520-527. DOI: 10.1080/09537104.2017.1349308. View

10.

Mannucci P, Canciani M, Forza I, Lussana F, Lattuada A, Rossi E . Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 2001; 98(9):2730-5. DOI: 10.1182/blood.v98.9.2730. View

11.

Flores B, Trivedi H, Robson S, Bonder A . Hemostasis, bleeding and thrombosis in liver disease. J Transl Sci. 2018; 3(3). PMC: 6136435. DOI: 10.15761/JTS.1000182. View

12.

Boks A, Brommer E, Schalm S, van Vliet H . Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology. 1986; 6(1):79-86. DOI: 10.1002/hep.1840060115. View

13.

Schepis F, Turco L, Bianchini M, Villa E . Prevention and Management of Bleeding Risk Related to Invasive Procedures in Cirrhosis. Semin Liver Dis. 2018; 38(3):215-229. DOI: 10.1055/s-0038-1660523. View

14.

Saja M, Abdo A, Sanai F, Shaikh S, Abdel Gader A . The coagulopathy of liver disease: does vitamin K help?. Blood Coagul Fibrinolysis. 2012; 24(1):10-7. DOI: 10.1097/MBC.0b013e32835975ed. View

15.

Khoury T, Ayman A, Cohen J, Daher S, Shmuel C, Mizrahi M . The Complex Role of Anticoagulation in Cirrhosis: An Updated Review of Where We Are and Where We Are Going. Digestion. 2016; 93(2):149-59. DOI: 10.1159/000442877. View

16.

Tateishi R, Seike M, Kudo M, Tamai H, Kawazoe S, Katsube T . A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation. J Gastroenterol. 2018; 54(2):171-181. PMC: 6349796. DOI: 10.1007/s00535-018-1499-2. View

17.

Kumar M, Ahmad J, Maiwall R, Choudhury A, Bajpai M, Mitra L . Thromboelastography-Guided Blood Component Use in Patients With Cirrhosis With Nonvariceal Bleeding: A Randomized Controlled Trial. Hepatology. 2019; 71(1):235-246. DOI: 10.1002/hep.30794. View

18.

Douros A, Azoulay L, Yin H, Suissa S, Renoux C . Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury. J Am Coll Cardiol. 2018; 71(10):1105-1113. DOI: 10.1016/j.jacc.2018.01.009. View

19.

Bosch J, Thabut D, Bendtsen F, DAmico G, Albillos A, Abraldes J . Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology. 2004; 127(4):1123-30. DOI: 10.1053/j.gastro.2004.07.015. View

20.

Terrault N, Hassanein T, Howell C, Joshi S, Lake J, Sher L . Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure. J Hepatol. 2014; 61(6):1253-9. DOI: 10.1016/j.jhep.2014.07.007. View